(19)
(11) EP 2 552 452 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.01.2016 Bulletin 2016/02

(45) Mention of the grant of the patent:
19.08.2015 Bulletin 2015/34

(21) Application number: 11709746.9

(22) Date of filing: 24.03.2011
(51) International Patent Classification (IPC): 
A61K 31/675(2006.01)
A61K 31/517(2006.01)
A61K 31/662(2006.01)
A61P 35/00(2006.01)
 A61K 45/06(2006.01)
A61K 31/522(2006.01)
A61K 39/395(2006.01)
(86) International application number:
PCT/EP2011/054548
(87) International publication number:
WO 2011/120870 (06.10.2011 Gazette 2011/40)

(54)

EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer

EGFR-Inhibitor und antivirales Mittel zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung und/oder Vorbeugung und/oder Abschwächung von Krebs

Inhibiteur EGFR et agent antiviral pour une utilisation simultanée, séparée ou séquentielle pour le traitement, la prévention et/ou la palliation du cancer

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 01.04.2010 EP 10290177

(43) Date of publication of application:
06.02.2013 Bulletin 2013/06

(73) Proprietors:
  • Institut Gustave Roussy (IGR)
    94800 Villejuif (FR)
  • Université Paris-Sud 11
    91405 Orsay Cedex (FR)

(72) Inventors:
  • DEUTSCH, Eric
    F-75004 Paris (FR)
  • VOZENIN, Marie Catherine
    F-91580 Villeneuve Sur Auvers (FR)
  • BOURHIS, Jean
    F-92330 Sceaux (FR)

(74) Representative: Paris, Fabienne et al
Ernest Gutmann - Yves Plasseraud S.A.S. 3, rue Auber
75009 Paris
75009 Paris (FR)


(56) References cited: : 
WO-A2-2006/047716
   
  • LIMSUKON A ET AL: "Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy", CHEST, THE COLLEGE, CHICAGO, IL, US LNKD- DOI:10.1378/CHEST.08-2639, vol. 136, no. 3, 1 September 2009 (2009-09-01), pages 924-926, XP008125703, ISSN: 0012-3692
  • LOYO M ET AL: "Aggressive recurrent respiratory papillomatosis in a neonate", INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.IJPORL.2008.02.022, vol. 72, no. 6, 1 June 2008 (2008-06-01), pages 917-920, XP022639209, ISSN: 0165-5876 [retrieved on 2008-04-18]
  • HERRERA F G ET AL: "Molecular targeted agents combined with chemo-radiation in the treatment of locally advanced cervix cancer", REVIEWS ON RECENT CLINICAL TRIALS, BENTHAM SCIENCE PUBLISHERS, NL LNKD- DOI:10.2174/157488708784223835, vol. 3, no. 2, 1 May 2008 (2008-05-01), pages 111-120, XP008125405, ISSN: 1574-8871
  • ANDREI G ET AL: "ANTIPROLIFERATIVE EFFECTS OF ACYCLIC NUCLEOSIDE PHOSPHONATES ON HUMAN PAPILLOMAVIRUS (HPV)-HARBORING CELL LINES COMPARED WITH HPV-NEGATIVE CELL LINES", ONCOLOGY RESEARCH, PERGAMON PRESS, NEW YORK, NY, US, vol. 10, no. 10, 1 January 1998 (1998-01-01), pages 523-531, XP008046881, ISSN: 0965-0407
  • ANDREI GRACIELA ET AL: "Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells", 2001, ONCOLOGY RESEARCH, VOL. 12, NR. 9-10, PAGE(S) 397-408, XP008126676, ISSN: 0965-0407 abstract
  • HOSTETLER KARL Y ET AL: "Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 1, January 2006 (2006-01), pages 156-159, XP002599768, ISSN: 1535-7163
  • BOSTROM B ET AL: "Gefitinib therapy for life-threatening laryngeal papillomatosis", ARCHIVES OF OTOLARYNGOLOGY HEAD AND NECK SURGERY, AMERICAN MEDICAL ASSOCIATION, US LNKD- DOI:10.1001/ARCHOTOL.131.1.64, vol. 131, no. 1, 1 January 2005 (2005-01-01), pages 64-67, XP008125409, ISSN: 0886-4470
  • FENG WEI ET AL: "Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.", INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2009 LNKD- PUBMED:19079619, vol. 2, no. 3, 2009, pages 249-260, XP002599769, ISSN: 1936-2625
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).